Compare KITT & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | ENVB |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.1M |
| IPO Year | N/A | 2000 |
| Metric | KITT | ENVB |
|---|---|---|
| Price | $1.53 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 347.1K | 155.8K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $0.56 |
| 52 Week High | $6.93 | $13.25 |
| Indicator | KITT | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 32.47 |
| Support Level | $0.75 | $0.58 |
| Resistance Level | $1.70 | $2.13 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 3.47 | 13.57 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.